Oxford Pharmascience’s H1 results highlight the significant potential of its NSAID pipeline. The £20m equity capital raise undertaken during the period should enable the group to negotiate commercialisation deals from a position of strength whilst it continues to progress development of its product pipeline. Headline OXPzeroTM Ibuprofen endoscopy data remains expected in Q4 2015 along with complete PK data, and an optimisation programme for OXPzeroTM Naproxen is underway to realise its full pote ....
